Monitor for longer-term clinical data from REVEAL Phase 1/2 expected later this quarter, which will be a more significant catalyst. ASGCT presentation (May 11-15) could drive near-term upside.
TSHA drugs
TSHA drug pipeline →How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Apr 28 $6.30entry
- T+1 · 7mo ago +0.87%α +0.88% · $6.36
- T+5 · 7mo ago +5.40%α +3.71% · $6.64
- T+20 · 6mo ago −11.27%α −16.74% · $5.59
- T+60 · 4mo ago −7.46%α −11.45% · $5.83
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Taysha Gene Therapies announced positive preclinical in vitro data for TSHA-102, showing scAAV9 enables ~30-fold higher MeCP2 expression vs. ssAAV9 and miniMeCP2 is functionally comparable to full-length MeCP2, supporting its Rett syndrome gene therapy design. Data will be presented at ASGCT Annual Meeting (May 11-15, 2026), with longer-term clinical data from REVEAL Phase 1/2 expected later this quarter.
Key Facts
- scAAV9 enabled ~30-fold higher MeCP2 expression compared to ssAAV9 in neuronal cells
- MiniMeCP2 protein demonstrated functional comparability to full-length MeCP2 across molecular and biochemical assays
- Data support translational potential of TSHA-102's construct design for lumbar IT administration
- Longer-term safety and efficacy data from Part A REVEAL Phase 1/2 expected later this quarter
Financial Impact
Preclinical data validation; no financial impact disclosed.
Risk Factors
- Clinical trial risks: efficacy/safety data may not replicate preclinical findings
- Regulatory risks: FDA approval uncertain
- Funding risk: clinical-stage biotech may require additional capital
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3282099 |
Track record
14 reports on TSHA
The track record builds as more bullish or bearish reports settle.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $4.06 Now $4.06 −0.00% settles Feb 16
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $4.21 Now $4.06 −3.56% settles Feb 10
- Aug 11, 202613w ago Press Release Neutral 5/10 Entry $6.41 to $4.09 Now $4.06 −36.61% ▼ −36.14% −31.03% vs SPY
- Jun 25, 202620w ago 8-K Mixed 5/10 Entry $6.34 to $5.04 Now $4.06 −35.96% ▼ −20.50% −26.61% vs SPY
- Jun 25, 202620w ago 424B5 Bearish 6/10 Entry $6.34 to $5.04 Now $4.06 +35.96% ▲ +20.50% +26.61% vs SPY
- Jun 24, 202620w ago Press Release Bearish 7/10 Entry $6.21 to $5.02 Now $4.06 +34.62% ▲ +19.16% +22.89% vs SPY
- Jun 5, 202623w ago Press Release Neutral 2/10 Entry $5.50 to $5.69 Now $4.06 −26.18% ▲ +3.45% −0.55% vs SPY
- May 6, 202627w ago 8-K Neutral 5/10 No price data
- May 6, 202627w ago Press Release Mixed 7/10 Entry $6.98 to $5.86 Now $4.06 −41.83% ▼ −16.05% −18.11% vs SPY
- Apr 29, 202628w ago Press Release Neutral 1/10 Entry $6.27 to $5.52 Now $4.06 −35.25% ▼ −11.96% −16.07% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers